Verona Pharma Corp (VRNA): קונצנזוס שווי הוגן

Verona Pharma plc (VRNA) is implementing advanced COPD therapy methods, leveraging the market launch of Ohtuvayre and expansion across Europe. The business model is based on low costs during mass production of inhalers following patenting, while the consensus forecast stands at 106.78. This chart of the price trend demonstrates the asset's dynamics. Verona Pharma plc (VRNA) has created a unique segment in lung treatment, eliminating pressure from manufacturers of low-cost generics.

The consensus target price chart reflects market expectations for the implementation of Verona Pharma (VRNA) eco-friendly gasless inhalers, converting ESG innovations into asset value. This indicator is calculated as the average target price from leading agencies, capturing microstructural valuation shifts to model stress scenarios. Analyzing this curve allows investors to determine the fundamental capital margin of safety and avoid unjustified risks when entering a position.